Drug Launch, Market Activity, Appointments, and Special Meeting of Shareholders - Research Reports on Teva, Universal Health, Tenet, Allergan and Valeant

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, September 9, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Teva Pharmaceutical Industries Limited (NYSE: TEVA), Universal Health Services Inc. (NYSE: UHS), Tenet Healthcare Corp. (NYSE: THC), Allergan Inc. (NYSE: AGN) and Valeant Pharmaceuticals International, Inc. (NYSE: VRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6317-100free.

--
Teva Pharmaceutical Industries Limited Research Reports
On September 4, 2014, Teva Pharmaceuticals Industries Limited (Teva) announced the launch of the generic equivalent to Baraclude® (Entecavir) Tablets, 0.5mg and 1mg, in the U.S. The Company said that it was first to file for the U.S. regulatory approval for generic Baraclude, making it eligible for 180 days of marketing exclusivity. Teva added that Baraclude® (Entecavir) Tablets, 0.5mg and 1mg, marketed by Bristol-Myers Squibb, had annual sales of approximately $328 million in the U.S., according to IMS data as of June 2014. The full research reports on Teva are available to download free of charge at:

http://www.analystsreview.com/Sep-09-2014/TEVA/report.pdf

--
Universal Health Services Inc. Research Reports
On September 4, 2014, the stock of Universal Health Services Inc. (Universal health) declined 3.10% to end the trading session at $108.00. After opening at $111.26, Universal Health's stock traded in the range of $105.40 - $112.03. The stock had hit a fresh 52-week high of $115.64 in the previous trading session. Shares in Universal Health have gained 1.05% in the last one month, compared to the Dow Jones Industrial Average which increased 3.90% during that period. Universal Health's stock is currently trading above its 50-day and 200-day moving averages of $103.54 and $87.78, respectively. The full research reports on Universal Health are available to download free of charge at:

http://www.analystsreview.com/Sep-09-2014/UHS/report.pdf

--
Tenet Healthcare Corp. Research Reports
On September 4, 2014, Tenet Healthcare Corp. (Tenet Healthcare) reported the appointment of Matt Cowley as CEO of its Arizona health plan operations, effective September 22, 2014. In his new role, Cowley will oversee the strategic operations of Phoenix Health Plan, LLC, and Phoenix Health Plans, Inc. In addition, Cowley will also serve as President and Chief Operating Officer of Advantage Healthcare Management Company, which provides management and administrative services for Tenet's health plans across the U.S. "Matt's extensive experience with Medicaid and Medicare insurance plans will serve him well as he positions the Arizona health plans as high-value insurers within the state," said Phillip Roe, Senior Vice President of finance and head of health plan operations at Tenet Healthcare. Cowley has previously worked as the head of Medicare products for Aetna-managed Mercy Care Plan in Arizona. The full research reports on Tenet are available to download free of charge at:

http://www.analystsreview.com/Sep-09-2014/THC/report.pdf

--
Allergan Inc. Research Reports
On September 4, 2014, Allergan Inc. (Allergan) issued an update on the validity of the written requests it received from shareholders via Pershing Square Capital Management, L.P. ("Pershing Square") for conducting a Special Meeting of Stockholders (the Special Meeting). The Company stated that a review conducted by Allergan and its independent inspector found that Pershing Square has delivered requests that comply as to form with Allergan's bylaws from stockholders owning more than 25% of Allergan's shares, which does not include the additional requests from stockholders owning 2.8% of Allergan's shares that were delivered on September 3, 2014. Allergan informed that it is scheduled to hold a Special Meeting on December 18, 2014. The full research reports on Allergan are available to download free of charge at:

http://www.analystsreview.com/Sep-09-2014/AGN/report.pdf

--
Valeant Pharmaceuticals International, Inc. Research Reports
On September 4, 2014, the stock of Valeant Pharmaceuticals International, Inc. (Valeant) fell 1.44% to end the trading session at $117.32. During the session, shares in Valeant opened at $118.89, and fluctuated in the range of $117.02 - $119.97, with a total of 1.51 million shares changing hands. Valeant's stock has increased by 6.02% in the last one month, compared to the Dow Jones Industrial Average, which increased 3.90% during that period. Valeant's stock is currently trading below its 50-day and 200-day moving averages of $118.72 and $125.51, respectively. The full research reports on Valeant are available to download free of charge at:

http://www.analystsreview.com/Sep-09-2014/VRX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…